sorafenib has been researched along with Bladder Cancer in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Chen, JN; Cheng, L; He, YZ; Li, QY; Li, T; Liu, G; Qin, TS; Sun, YX; Wei, Y; Yao, D; Zhang, GJ | 1 |
| Arapi, V; Franzén, B; Hååg, P; Holmsten, K; Lewensohn, R; Sandström, P; Shah, CH; Ullén, A; Viktorsson, K | 1 |
| Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ | 1 |
| Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N | 1 |
| Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F | 1 |
| Albers, P; Greife, A; Hader, C; Knievel, J; Lübke, T; Niegisch, G; Schmitz, I; Schulz, WA | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Elfiky, AA; Rosenberg, JE | 1 |
| DiPaola, R; Dreicer, R; Eleff, M; Li, H; Roth, BJ; Stein, M; Wilding, G | 1 |
| Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Miroglu, C; Silay, MS | 1 |
2 review(s) available for sorafenib and Bladder Cancer
| Article | Year |
|---|---|
Targeting angiogenesis in bladder cancer.
Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2009 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2010 |
3 trial(s) available for sorafenib and Bladder Cancer
| Article | Year |
|---|---|
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Evaluation; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Urinary Bladder Neoplasms | 2009 |
8 other study(ies) available for sorafenib and Bladder Cancer
| Article | Year |
|---|---|
Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Glutathione Peroxidase; Humans; Intracellular Space; Molecular Docking Simulation; Protein Conformation; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship; Urea; Urinary Bladder Neoplasms | 2020 |
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
Topics: Biomarkers; Carcinoma, Transitional Cell; Extracellular Vesicles; Humans; Sorafenib; Toll-Like Receptor 3; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Interleukin-27; Niacinamide; Phenylurea Compounds; Sorafenib; Urinary Bladder Neoplasms | 2017 |
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2014 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; ras Proteins; Sorafenib; Urinary Bladder Neoplasms | 2010 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2007 |